In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity

Abstract

Cardiac dysfunction is a major side effect of trastuzumab therapy for patients with HER2-positive breast cancer. Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy. In the present study, the preservability effects of carvedilol on trastuzumab-induced left ventricular (LV) dysfunction and the reversibility of trastuzumab-induced cardiotoxicity were evaluated in Wistar rats by echocardiography method. We showed that trastuzumab treatment of rats could induce the LV dysfunction through increasing the LV internal systolic diameter (LVIDs), increasing the end-systolic volume (ESV), decreasing the ejection fraction (EF), and decreasing the fractional shortening (FS). These parameters were not reversed after 14 days of stopping trastuzumab administration. Interestingly, carvedilol improved LVIDs, ESV, EF, and FS. Collectively, the results of this study have verified clinical observations which simultaneously administration of carvedilol may be considered as a possible therapeutic strategy to prevent trastuzumab-mediated LV dysfunction.

Key words

Trastuzumab - carvedilol - cardiotoxicity

• References

• 1 Wang J. et al. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+breast cancer: A pilot study. Medicine (Baltimore) 2019; 98 p e15872
• 2 Sato A. et al. Valvular heart disease as a possible predictor of trastuzumab‑induced cardiotoxicity in patients with breast cancer. Molecular and Clinical Oncology 2019; 10 p 37-42
• 3 Crone SA. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature medicine 2002; 8 p 459
• 4 Özcelik C. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proceedings of the National Academy of Sciences 2002; 99 p 8880-8885
• 5 Vermeulen Z, Segers VF, Keulenaer G.W.De. ErbB2 signaling at the crossing between heart failure and cancer. Basic research in cardiology 2016; 111 p 60
• 6 Zeglinski M. et al. Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’. Experimental & Clinical Cardiology 2011; 16 p 70
• 7 Tocchetti CG. et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail 2012; 14 p 130-137
• 8 Maurea N. et al. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. J Cardiovasc Med (Hagerstown) 2010; 11 p 861-868
• 9 Telli ML. et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Journal of Clinical Oncology 2007; 25 p 3525-3533
• 10 Montemurro F. et al. Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial. J Clin Oncol 2008; 26 p 2052-2053 author reply 2053-4
• 11 Popat S, Smith IE. Therapy insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects. Nature Reviews. Clinical Oncology 2008; 5 p 324
• 12 Gorini S. et al. Chemotherapeutic drugs and mitochondrial dysfunction: Focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev 2018; 2018 p 7582730
• 13 Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology 2015; 12 p 547
• 14 ElZarrad MK. et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 2013; 8 p e79543
• 15 Tanaka S. et al. Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors. Oxf Med Case Reports. 2017 2017. 07 omx038
• 16 Johnson TA, Singla DK. Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. Canadian journal of physiology and pharmacology 2018; 96 p 647-654
• 17 Coppola C. et al. Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. Onco Targets Ther 2016; 9 p 6785-6794
• 18 Spallarossa P. et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004; 37 p 837-846
• 19 Matsui H. et al. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65 p 1265-1274
• 20 Kalay N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48 p 2258-2262
• 21 Seicean S. et al. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013; 6 p 420-426
• 22 Guglin M. et al. Randomized trial of lisinopril vs. carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 2019; 73 p 2859-2868
• 23 Gujral DM, Lloyd G, Bhattacharyya S. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy±trastuzumab. The Breast 2018; 37 p 64-71
• 24 Council NR. Guide for the care and use of laboratory animals. 2010. National Academies Press;
• 25 Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomedicine & Pharmacotherapy 2017; 93 p 17-26
• 26 Riccio G. et al. Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. Front Physiol 2018; 9 p 38
• 27 Piotrowski G. et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2–a prospective study. Archives of medical science: AMS 2012; 8 p 227
• 28 Spielmann M. et al. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. Journal of Clinical Oncology 2009; 27 p 6129-6134
• 29 Jassal DS. et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009; 22 p 418-424
• 30 Milano G. et al. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. J Am Soc Echocardiogr 2014; 27 p 568-579
• 31 Azar AD. et al. Echocardiographic evaluation of cardiac function in ischemic rats: value of m-mode echocardiography. Research in cardiovascular medicine 2014; 3: 4
• 32 Negishi K. et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. European Heart Journal–Cardiovascular Imaging 2013; 15 p 324-331
• 33 Gordon LI. et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. Journal of Biological Chemistry 2009; 284 p 2080-2087
• 34 Zheng W. et al. The Effects of Carvedilol on Cardiac Function and the AKT/XIAP Signaling Pathway in Diabetic Cardiomyopathy Rats. Cardiology 2017; 136 p 204-211
• 35 Endo R. et al. Carvedilol Suppresses Apoptosis and Ion Channel Remodelling of HL-1 Cardiac Myocytes Expressing E334K cMyBPC. Drug research 2016; 66 p 126-129
• 36 Pereira C. , G et al. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Current pharmaceutical design 2011; 17 p 2113-2129